Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit
Chimerix (NASDAQ:CMRX) announced participation in the Cowen and Company 2nd Annual Virtual Oncology Innovation Summit. CEO Mike Sherman and CFO Mike Andriole will engage in a fireside chat on May 20, 2021, at 10:00 a.m. ET. A live audio webcast will be accessible on Chimerix's Investor Relations section, archived for 90 days.
Chimerix focuses on developing innovative treatments for cancer and other serious diseases, with key programs including brincidofovir, ONC201, and dociparstat sodium.
- None.
- None.
DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the Cowen and Company 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 10:00 a.m. ET.
A live audio webcast of the chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
When is Chimerix participating in the Virtual Oncology Innovation Summit?
Where can I watch the Chimerix fireside chat?
What is Chimerix's focus in drug development?
What are the key drugs in Chimerix's clinical programs?
How long will the webcast of Chimerix's chat be available?
